Frenkel Ran's Form 4 filing
Karyopharm Therapeutics Inc. (KPTI) · filed Feb 22, 2022
- Accession no.
- 0001209191-22-011643
- Filed
- Feb 22, 2022
- Trade date
- Feb 17, 2022
- Filing delay
- 5 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction. Open-market sales total $35.5K. It was filed 5 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Frenkel RanCIK 0001623108 | Officer (EVP, Chief Dev. Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 17, 2022 | Common Stock | SSaleDisposed | −2,929 | $12.12F2 | −$35,499.48 | 101,703 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on February 17, 2022 on behalf of a group of employees of Karyopharm Therapeutics Inc. to satisfy the payment of withholding tax liability of such employees.
Referenced by the price of 1 transaction in Table I.